Cargando…
Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
BACKGROUND: To investigate the in vitro and in vivo antitumor activity of dual PI3K/mTOR inhibitor BEZ235 (NVP-BEZ235) in HER2-positive gastric cancer. METHODS: HER2-positive breast cancer cell line (BT474), HER2-positive (NCI-N87 and SNU216), and HER2-negative (MKN45) gastric cancer cell lines were...
Autores principales: | Zhu, Yan, Tian, Tiantian, Zou, Jianling, Wang, Qiwei, Li, Zhongwu, Li, Yanyan, Liu, Xijuan, Dong, Bin, Li, Na, Gao, Jing, Shen, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641417/ https://www.ncbi.nlm.nih.gov/pubmed/26560145 http://dx.doi.org/10.1186/s12885-015-1900-y |
Ejemplares similares
-
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
por: ZHANG, CHANG-HUA, et al.
Publicado: (2013) -
BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
por: Füreder, Thorsten, et al.
Publicado: (2010) -
Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
por: Lin, Shu-Fu, et al.
Publicado: (2012) -
Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018) -
BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)